Literature DB >> 18472981

Clinical studies with oral lipid based formulations of poorly soluble compounds.

Dimitrios G Fatouros1, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz.   

Abstract

This work is an attempt to give an overview of the clinical data available on lipid based formulations. Lipid and surfactant based formulations are recognized as a feasible approach to improve bioavailability of poorly soluble compounds. However not many clinical studies have been published so far. Several drug products intended for oral administration have been marketed utilizing lipid and surfactant based formulations. Sandimmune((R)) and Sandimmune Neoral((R)) (cyclosporin A, Novartis), Norvir((R)) (ritonavir), and Fortovase((R)) (saquinavir) have been formulated in self-emulsifying drug delivery systems (SEDDS). This review summarizes published pharmacokinetic studies of orally administered lipid based formulations of poorly aqueous soluble drugs in human subjects. Special attention has been paid to the physicochemical characteristics of the formulations, when available and the impact of these properties on the in vivo performance of the formulation. Equally important is the effect of concurrent food intake on the bioavailability of poorly soluble compounds. The effect of food on the bioavailability of compounds formulated in lipid and surfactant based formulations is also reviewed.

Entities:  

Keywords:  SEDDS; emulsions; food effect; human clinical studies; lipid formulations; lipophilic compounds; pharmacokinetics; poorly soluble compounds

Year:  2007        PMID: 18472981      PMCID: PMC2374933     

Source DB:  PubMed          Journal:  Ther Clin Risk Manag        ISSN: 1176-6336            Impact factor:   2.423


  60 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Plasma concentrations after oral administration of different pharmaceutical preparations of clomethiazole.

Authors:  M Fischler; E P Frisch; B Ortengren
Journal:  Acta Pharm Suec       Date:  1973-12

3.  Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation.

Authors:  J M Kovarik; E A Mueller; J B van Bree; W Tetzloff; K Kutz
Journal:  J Pharm Sci       Date:  1994-03       Impact factor: 3.534

4.  Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; J Grevel; P W Lücker; K Kutz
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

Review 5.  The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine.

Authors:  D W Holt; E A Mueller; J M Kovarik; J B van Bree; K Kutz
Journal:  Transplant Proc       Date:  1994-10       Impact factor: 1.066

6.  Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.

Authors:  Meret Martin-Facklam; Jürgen Burhenne; Reinhard Ding; Ruth Fricker; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

7.  Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to cyclosporine.

Authors:  Johanna Mercke Odeberg; Peter Kaufmann; Karl Gunnar Kroon; Peter Höglund
Journal:  Eur J Pharm Sci       Date:  2003-12       Impact factor: 4.384

8.  Examination of some factors responsible for a food-induced increase in absorption of atovaquone.

Authors:  P E Rolan; A J Mercer; B C Weatherley; T Holdich; H Meire; R W Peck; G Ridout; J Posner
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

9.  Cyclosporin nanoparticulate lipospheres for oral administration.

Authors:  Tania Bekerman; Jacob Golenser; Abraham Domb
Journal:  J Pharm Sci       Date:  2004-05       Impact factor: 3.534

10.  The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.

Authors:  M M Malingré; J H Schellens; O Van Tellingen; M Ouwehand; H A Bardelmeijer; H Rosing; F J Koopman; M E Schot; W W Ten Bokkel Huinink; J H Beijnen
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

View more
  15 in total

Review 1.  Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.

Authors:  Angel Tan; Shasha Rao; Clive A Prestidge
Journal:  Pharm Res       Date:  2013-06-18       Impact factor: 4.200

2.  Design and formulation technique of a novel drug delivery system for azithromycin and its anti-bacterial activity against Staphylococcus aureus.

Authors:  M Joyce Nirmala; Amitava Mukherjee; N Chandrasekaran
Journal:  AAPS PharmSciTech       Date:  2013-06-26       Impact factor: 3.246

3.  Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation.

Authors:  Cedar H A Boakye; Ketan Patel; Apurva R Patel; Henrique A M Faria; Valtencir Zucolotto; Stephen Safe; Mandip Singh
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

4.  First in man bioavailability and tolerability studies of a silica-lipid hybrid (Lipoceramic) formulation: a Phase I study with ibuprofen.

Authors:  Angel Tan; Nasrin Ghouchi Eskandar; Shasha Rao; Clive A Prestidge
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

5.  Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.

Authors:  Xingwang Zhang; Tianpeng Zhang; Yali Lan; Baojian Wu; Zhihai Shi
Journal:  AAPS PharmSciTech       Date:  2015-07-18       Impact factor: 3.246

6.  Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs.

Authors:  Nicky Thomas; René Holm; Mats Garmer; Jens Jakob Karlsson; Anette Müllertz; Thomas Rades
Journal:  AAPS J       Date:  2012-11-21       Impact factor: 4.009

7.  Molecular Dynamics Simulations and Experimental Results Provide Insight into Clinical Performance Differences between Sandimmune® and Neoral® Lipid-Based Formulations.

Authors:  Dallas B Warren; Shadabul Haque; Mitchell P McInerney; Karen M Corbett; Endri Kastrati; Leigh Ford; Hywel D Williams; Vincent Jannin; Hassan Benameur; Christopher J H Porter; David K Chalmers; Colin W Pouton
Journal:  Pharm Res       Date:  2021-09-24       Impact factor: 4.200

8.  Pharmacokinetics of quercetin-loaded nanodroplets with ultrasound activation and their use for bioimaging.

Authors:  Li-Wen Chang; Mei-Ling Hou; Shuo-Hui Hung; Lie-Chwen Lin; Tung-Hu Tsai
Journal:  Int J Nanomedicine       Date:  2015-04-17

9.  Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation.

Authors:  Ling Zhao; Yumeng Wei; Yu Huang; Bing He; Yang Zhou; Junjiang Fu
Journal:  Int J Nanomedicine       Date:  2013-10-02

10.  Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal.

Authors:  Manal A Elsheikh; Yosra S R Elnaggar; Eman Y Gohar; Ossama Y Abdallah
Journal:  Int J Nanomedicine       Date:  2012-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.